SOPHiA GENETICS SA Form 4 Filings

SOPHiA GENETICS SA (SOPH) reported that Chief Scientific Officer Zhenyu Xu sold 10,000 Ordinary Shares on August 27, 2026 in an open-market or private transaction under a Rule 10b5-1(c) trading plan. The weighted average sale price was $8.9096 per share, and Xu now holds 556,887 Ordinary Shares directly.

SOPHiA GENETICS SA (SOPH) reported that Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares on 2026-08-25. The shares were sold at a weighted average price of $8.6793 per share, in multiple trades between $8.37 and $8.84, pursuant to a Rule 10b5-1(c) trading plan. Following this transaction, Menu owned 213,387 Ordinary Shares directly.

SOPHiA GENETICS SA (SOPH) director Kathy L. Hibbs reported selling 6,250 Ordinary Shares on 2026-08-25 in an open market or private transaction at a weighted average price of $8.6773 per share, with individual trade prices ranging from $8.31 to $8.83. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan, and following this transaction she directly owns 103,242 Ordinary Shares.

SOPHiA GENETICS SA (SOPH) reported that Chief Technology Officer Abhimanyu Verma sold a total of 10,000 Ordinary Shares in two open-market transactions. On August 19, 2026, he sold 5,000 shares at $8.20 per share, and on August 24, 2026, he sold 5,000 shares at $8.80 per share. Both transactions were executed under a duly adopted Rule 10b5-1(c) trading plan, indicating they were pre-arranged.

SOPHiA GENETICS SA (SOPH) reported that Chief People Officer Manuela Valente exercised share options for 10,000 Ordinary Shares at an exercise price of $3.20 per share and, on the same date, sold 10,000 Ordinary Shares at a weighted average price of $7.9439 per share. The transactions were made pursuant to a duly adopted Rule 10b5-1(c) trading plan. The exercised options were fully vested, and following this exercise she continues to hold 554,276 derivative share options across remaining grant tranches with varying exercise prices, with the exercised option series expiring on January 1, 2029.

SOPHiA GENETICS SA (SOPH) reported that Chief Scientific Officer Zhenyu Xu sold a total of 20,000 Ordinary Shares in open-market or private transactions under a duly adopted Rule 10b5-1(c) trading plan. The sales occurred on August 19–21, 2026, at weighted average prices of $7.94, $8.41, and $8.40, each representing multiple trades within narrow price ranges.

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 Ordinary Shares of the company on 2026-08-12 in an open-market transaction under a duly adopted Rule 10b5-1(c) trading plan. The weighted average sale price was $7.5159 per share, with individual trades executed between $7.40 and $7.60 per share. Following this sale, Menu directly holds 218,387 Ordinary Shares.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported a sale of 4,000 Ordinary Shares on August 13, 2026. The shares were sold at a weighted average price of $7.5191 per share, in multiple trades between $7.43 and $7.62. After this transaction, Xu directly holds 586,887 Ordinary Shares. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan.

SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported a sale of 5,000 Ordinary Shares of SOPH on 2026-08-07 at $7.60 per share in an open market or private transaction. After this transaction, he directly holds 182,171 Ordinary Shares. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan.

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported two non-derivative stock sales of Ordinary Shares pursuant to a duly adopted Rule 10b5-1(c) trading plan. On August 7, 2026, he sold 20,000 shares at a weighted average price of $7.227, in multiple trades between $7.20 and $7.27. On August 10, 2026, he sold 8,500 shares at a weighted average price of $7.6081, in multiple trades between $7.50 and $7.80. Post-transaction share holdings are not specified in this filing.

SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu reported option exercises and share sales in early August 2026. He exercised options for 10,000 Ordinary Shares at $3.2800 per share and sold 20,000 Ordinary Shares at prices between $7.00 and $7.56 under a Rule 10b5-1(c) trading plan, while retaining 975,041 derivative share options.

SOPHiA GENETICS SA reported that Chief Technology Officer Abhimanyu Verma sold 5,000 Ordinary Shares on 2026-08-04 at a weighted average price of $6.9543 per share, in multiple trades between $6.95 and $6.98. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan, and Verma now holds 187,171 Ordinary Shares directly.

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported selling 20,000 Ordinary Shares on 2026-08-04 in an open-market transaction under a duly adopted Rule 10b5-1(c) trading plan. The shares were sold at a weighted average price of $6.9206, within a $6.90–$6.98 range, leaving him with 3,472,822 shares held directly.

SOPHiA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold 10,000 Ordinary Shares on August 4, 2026 at a weighted average price of $6.9168 per share under a duly adopted Rule 10b5-1(c) trading plan, in trades priced between $6.90 and $6.95, leaving 600,887 shares held directly.

SOPHiA GENETICS SA reported that Chief Medical Officer Philippe Menu executed a sale of 5,000 Ordinary Shares on 2026-07-27. The shares were sold at a weighted average price of $5.6611 per share, with individual trades occurring between $5.57 and $5.83. The sale was carried out under a duly adopted Rule 10b5-1(c) trading plan, indicating it was pre-arranged. After this transaction, Menu directly holds 223,387 Ordinary Shares of SOPHiA GENETICS SA.

SOPHiA GENETICS SA Executive Chairman and director Jurgi Camblong reported option exercises and share sales executed pursuant to a duly adopted Rule 10b5-1(c) trading plan. On July 20, 2026, he exercised options for 4,581 ordinary shares at $3.16 per share and sold 4,581 shares at a weighted average $6.1654, in multiple trades between $6.10 and $6.20, plus 19,800 shares at a weighted average $6.3233, in trades between $6.30 and $6.37. On July 21, 2026, he sold 20,000 ordinary shares at a weighted average $6.6327, in trades between $6.60 and $6.72. A footnote states he continues to hold 4,641,476 derivative share options across remaining grant tranches.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu completed an open-market sale of 5,000 Ordinary Shares on 2026-07-13 at a weighted average price of $5.701 per share, with individual trade prices between $5.55 and $5.79, pursuant to a duly adopted Rule 10b5-1(c) trading plan. Following the transaction, he directly holds 228,387 Ordinary Shares.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu completed an open-market sale of 4,000 Ordinary Shares on July 13, 2026, at a weighted average price of $5.7048 per share. The transaction was made under a duly adopted Rule 10b5-1(c) trading plan, and Xu now directly holds 610,887 Ordinary Shares.

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 8,500 Ordinary Shares on July 10, 2026 at a weighted average price of $5.6225 per share. The transaction was made pursuant to a Rule 10b5-1(c) trading plan, and he continues to hold 3,532,622 shares directly. The shares were sold in multiple trades at prices between $5.53 and $5.77.

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 17,685 Ordinary Shares at an average price of $5.2772 per share. According to the filing, the shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on July 3, 2026, under a pre-established Rule 10b5-1(c) trading plan. After this transaction, Camblong directly holds 3,541,122 Ordinary Shares, indicating the sale is small relative to his remaining stake and was executed on a non-discretionary basis.

SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,592 Ordinary Shares in an open‑market transaction. The weighted average sale price was $5.2886 per share. According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock units that vested on July 2, 2026 and was executed under a pre‑established Rule 10b5‑1(c) trading plan. After this tax‑related sale, Cardoza directly holds 309,092 Ordinary Shares.

SOPHiA GENETICS SA Chief People Officer Manuela Valente sold 4,241 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of $5.053 per share to cover tax withholding obligations tied to restricted stock units vesting on July 2 and July 3, 2026, under a pre-established Rule 10b5-1(c) trading plan. After this sale, she directly holds 210,450 Ordinary Shares.

SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported a sale of 5,285 Ordinary Shares in an open-market transaction. The weighted average sale price was about $5.10 per share, with individual trades between $4.97 and $5.41.

According to the footnotes, these shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on July 2 and July 3, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. After the sale, Verma directly holds 192,171 Ordinary Shares.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 7,393 Ordinary Shares in an open-market transaction at a weighted average price of $5.1727 per share. The sale was executed to cover tax withholding obligations from recent restricted stock unit vesting under a pre-established Rule 10b5-1(c) trading plan and does not represent a discretionary trade. Following this transaction, Xu directly holds 614,887 Ordinary Shares, indicating he retains a large continuing stake in the company.

SOPHiA GENETICS SA Chief Executive Officer Ross Muken reported an open-market sale of 9,838 Ordinary Shares at a weighted average price of $5.22 per share. According to the footnotes, the sale was made solely to satisfy tax withholding obligations tied to restricted stock units that vested on July 2 and July 3, 2026, under a pre-established Rule 10b5-1(c) trading plan and was not a discretionary trade. Following these transactions, he directly holds 670,651 Ordinary Shares. The shares were sold in multiple trades at prices between $4.97 and $5.43.

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported small insider sales tied to tax obligations. On July 6, 2026, he sold a total of 216 Ordinary Shares in open-market transactions at prices between $5.0251 and $5.0862 per share.

According to the footnotes, these were non-discretionary “sell to cover” trades executed to satisfy taxes from restricted stock units that vested on July 2 and July 3, 2026. After these transactions, he continues to hold 147,948 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 7,393 ordinary shares of the company on July 6, 2026 at a weighted average price of $5.1611 per share. According to the disclosure, these open-market sales were made to satisfy tax withholding obligations from restricted stock units that vested on July 2 and July 3, 2026, and were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. After the sale, Menu directly holds 233,387 ordinary shares, indicating he maintains a substantial ongoing equity position in the company.

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 22,486 Ordinary Shares at a weighted average price of $5.255 per share. According to the filing, the sale was made to satisfy tax withholding obligations from restricted stock unit vesting and was executed under a pre-established Rule 10b5-1(c) trading plan, described as non-discretionary. After this transaction, he directly holds 3,558,807 Ordinary Shares.

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported both option exercises and share sales in late June. On June 29–30, he sold a total of 83,679 Ordinary Shares in multiple open‑market transactions at prices including $6.30, $6.0215, $6.00 and $5.8670 per share, under a pre‑arranged Rule 10b5‑1(c) trading plan.

He also exercised share options to acquire 63,479 Ordinary Shares at an exercise price of $3.16 per share, converting previously granted options into stock. After these transactions, he directly holds 3,581,293 Ordinary Shares and continues to hold 4,646,057 derivative stock options across remaining grant tranches, indicating a substantial ongoing exposure to the company’s equity despite the sales.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported an exercise-and-sell transaction involving the company’s ordinary shares. He exercised 31,940 share options at an exercise price of $3.16 per share and sold a total of 51,442 ordinary shares in open-market trades at weighted average prices around $5.73–$5.84, in multiple transactions within disclosed ranges. These sales were made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following the transactions, he directly owns 3,601,493 ordinary shares and holds 4,709,536 derivative stock options across remaining grant tranches with varying exercise prices.

SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma sold 6,944 Ordinary Shares in an open-market transaction at a weighted average price of about $5.51 per share. According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock unit vesting under a pre-established Rule 10b5-1(c) trading plan and was not a discretionary trade. Following this tax-related sale, he continues to hold 197,456 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares on June 25, 2026 at a weighted average price of $5.5049 per share. The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following this sale, Menu directly holds 240,780 Ordinary Shares, indicating he retained a substantial position in the company.

SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported a small open-market sale of 774 Ordinary Shares. The shares were sold at a weighted average price of $5.3795 per share on June 22, 2026, and he held 310,684 shares afterward.

According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock units that vested on June 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary.

SOPHiA GENETICS SA President Ross Muken reported an open-market sale of 422 Ordinary Shares at a weighted average price of $5.3803 per share. According to the disclosure, the shares were sold in the open market solely to satisfy tax withholding obligations tied to the vesting of restricted stock units on June 18, 2026, under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. Following this small, tax-related transaction, he directly holds 680,489 Ordinary Shares.

SOPHiA GENETICS SA director Troy Cox received new equity awards tied to his board service. He was granted 19,724 restricted stock units, each representing one ordinary share valued at $5.46, bringing his direct holdings to 328,743 ordinary shares.

He also received options to purchase 28,818 ordinary shares at an exercise price of $5.46 per share, expiring on June 18, 2036, increasing his option holdings to 252,809. Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, contingent on his continued service.

SOPHiA GENETICS SA director Kathy L. Hibbs received new equity awards as part of her compensation. She was granted 19,724 restricted stock units, each representing one ordinary share, at a reference price of $5.46 per share. Following this award, she directly holds 109,492 ordinary shares.

She also received options to buy 28,818 ordinary shares at an exercise price of $5.46 per share, expiring on June 18, 2036, bringing her total option holdings to 218,569 share options. Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to her continued service.

SOPHiA GENETICS SA director Vincent Ossipow received equity compensation consisting of restricted stock units and options. On June 18, 2026 he was granted 19,724 RSUs, each representing one ordinary share, and 28,818 share options with a $5.46 exercise price. Both the RSUs and options vest 100% at the date of the company’s next scheduled annual shareholder meeting, subject to his continued service. Following these awards, he directly holds 522,860 ordinary shares and 138,569 options.

SOPHiA GENETICS SA director Jean-Michel Cossery reported receiving new equity awards as part of his compensation. He was granted 19,724 restricted stock units, each representing one ordinary share, and 28,818 share options with a conversion price of $5.46 per share.

Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to his continued service. Following these awards, Cossery directly holds 206,212 ordinary shares and 138,449 options.

SOPHiA GENETICS SA director Didier Hirsch received new equity awards as part of his compensation. He was granted 19,724 Ordinary Shares in the form of restricted stock units valued at $5.46 per share, bringing his direct share holdings to 240,220 Ordinary Shares.

He also received options to buy 28,818 Ordinary Shares at an exercise price of $5.46 per share, with 218,569 options held after the grant. Both the RSUs and the options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to his continued service.

SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu sold 4,000 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of $5.0141 per share across multiple trades within a $4.90 to $5.13 range. After this transaction, Xu Zhenyu directly holds 622,280 Ordinary Shares. The sale was executed pursuant to a duly adopted trading plan under Rule 10b5-1(c), indicating the trades were pre-scheduled rather than discretionary.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares in an open-market transaction at a weighted average price of $4.9504 per share. After this sale, he directly holds 245,780 Ordinary Shares. The trade was executed under a pre-arranged Rule 10b5-1(c) trading plan, meaning it was scheduled in advance rather than timed opportunistically.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 Ordinary Shares in an open-market transaction at a weighted average price of $5.2354 per share. Following the sale, he directly holds 3,620,995 shares.

The sale was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The shares were sold in multiple trades at prices ranging from $5.13 to $5.42.

SOPHiA GENETICS SA Chief Financial Officer George Cardoza bought 20,000 Ordinary Shares in an open-market purchase at $4.95 per share. After this transaction, he directly holds 311,458 Ordinary Shares. The purchase was made during an open trading window under the company’s insider trading policy.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.9548 per share. The transaction was executed on May 26, 2026 pursuant to a duly adopted Rule 10b5-1(c) trading plan.

After this sale, Menu directly holds 250,780 Ordinary Shares, indicating he retains a substantial equity position in the company. The sale price reflects multiple trades within a range of $4.78 to $5.01 per share, aggregated into the reported weighted average.

SOPHiA GENETICS SA President Ross Muken reported a small open-market sale of 761 Ordinary Shares at a weighted average price of $4.6006 per share. The shares were sold on May 19, 2026 to cover tax withholding obligations from restricted stock units that vested on May 18, 2026.

The filing states these sales were executed under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. After the transaction, Muken directly holds 680,911 Ordinary Shares, indicating this was a minor, routine tax-related disposition relative to his overall position.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 608 Ordinary Shares. The shares were sold at a weighted average price of $4.6015 per share on May 19, 2026, to satisfy tax withholding obligations arising from restricted stock units that vested on May 18, 2026.

According to the disclosure, these sales were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. Following this transaction, Xu directly holds 626,280 Ordinary Shares.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 4,486 Ordinary Shares in an open-market transaction at a weighted average price of $4.6049 per share. The shares were sold on May 19, 2026 to cover tax withholding obligations from restricted stock units that vested on May 18, 2026.

The filing states these sales were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After this transaction, Camblong directly holds 3,629,495 Ordinary Shares.

SOPHiA GENETICS SA’s Chief Medical Officer, Philippe Menu, sold 608 Ordinary Shares of the company on May 19, 2026 at a weighted average price of $4.6059 per share. According to the disclosure, these shares were sold in the open market solely to satisfy tax withholding obligations arising from restricted stock units that vested on May 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were pre-planned and not discretionary. Following this sale, Menu directly holds 255,780 Ordinary Shares.

SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported an open-market sale of 684 Ordinary Shares at a weighted average price of $4.6042 per share. According to the disclosure, the sale was made to satisfy tax withholding obligations from vesting restricted stock units under a pre-established Rule 10b5-1(c) trading plan and was not discretionary. Following this transaction, Van Well directly holds 345,052 Ordinary Shares.